-
| Exchange | LSE |
|---|---|
| Industry | Biotechnology |
| CurrencyCode | GBP |
| ISIN | GB00BMDQ2T15 |
| Sector | Healthcare |
| Market Cap | 3M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | -0.36 |
| Dividend Yield | None |
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ROQ.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025